It would mean effectively no value given to the U.S. Reimbursement at US$299 per scan ahead of schedule that significantly derisks the business, nor to the Imbio acquisition of 4 FDA / EMA AI diagnostic products (and counting) along with its growing commercial arrangements and revenue streams, nor to the Philips partnership, nor to the Outpatient clinic sign ups, nor to the Integral Diagnostics contract, and nor to other activities setting the foundation for growth .... makes sense...
Research, page-2264
-
- There are more pages in this discussion • 602 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add 4DX (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
41.5¢ |
Change
-0.020(4.60%) |
Mkt cap ! $170.3M | |||
| Open | High | Low | Value | Volume |
| 43.5¢ | 43.5¢ | 41.5¢ | $48.61K | 115.0K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 4 | 44047 | 41.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 43.0¢ | 6200 | 1 |
View Market Depth
| Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
| 4DX (ASX) Chart |